<DOC>
	<DOC>NCT00043875</DOC>
	<brief_summary>This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to the current therapy of pediatric patients age 1-24 months old with partial seizures. The medication used in this study has been approved by FDA for the adjunctive treatment of partial seizures in patients 2 years and older.</brief_summary>
	<brief_title>Pediatric Epilepsy Trial in Subjects 1-24 Months</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<criteria>INCLUSION CRITERIA: Have a confident diagnosis of epilepsy Must be experiencing 4 or more reliably detectable partial seizures per month while receiving at least 1 antiepileptic drug (AED) Must weigh at least 7 lbs if currently receiving enzyme inducing antiepileptic drugs (EIADs) OR weigh at least 15 lbs if currently receiving nonenzyme inducing antiepileptic drugs (nonEIADs) Have no underlying chronic metabolism problems Have normal lab results Have a normal electrocardiogram (ECG) EXCLUSION CRITERIA: Have a diagnosis of severe, progressive myoclonus. Have seizures not related to epilepsy. Have previously demonstrated sensitivity or allergic reaction to the study drug or its related compounds. Have progressive or unstable condition of the nervous system. Used experimental medication within 30 of enrollment into the study. Have any significant, chronic heart, kidney, liver or stomach/intestinal (GI) condition. Current use of the medication felbamate. Current use of adrenocorticotrophic hormone (ACTH). Following a ketogenic diet. Receiving vagal nerve stimulation (VNS).</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>partial seizures</keyword>
	<keyword>pediatric</keyword>
	<keyword>epilepsy</keyword>
</DOC>